Xueyang Jiang

1.3k total citations
34 papers, 1.0k citations indexed

About

Xueyang Jiang is a scholar working on Molecular Biology, Pharmacology and Computational Theory and Mathematics. According to data from OpenAlex, Xueyang Jiang has authored 34 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Pharmacology and 8 papers in Computational Theory and Mathematics. Recurrent topics in Xueyang Jiang's work include Cholinesterase and Neurodegenerative Diseases (9 papers), Computational Drug Discovery Methods (8 papers) and Alzheimer's disease research and treatments (5 papers). Xueyang Jiang is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (9 papers), Computational Drug Discovery Methods (8 papers) and Alzheimer's disease research and treatments (5 papers). Xueyang Jiang collaborates with scholars based in China, Saudi Arabia and United States. Xueyang Jiang's co-authors include Haopeng Sun, Feng Feng, Wenyuan Liu, Wei Qu, Siyu He, Yang Wang, Junting Zhou, Hongli Jiang, Yao Chen and Hongyu Yang and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Medicinal Chemistry and Phytochemistry.

In The Last Decade

Xueyang Jiang

30 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xueyang Jiang China 16 589 329 251 204 201 34 1.0k
Jinqiang Hou China 23 969 1.6× 187 0.6× 132 0.5× 271 1.3× 105 0.5× 54 1.3k
Carles Galdeano Spain 18 897 1.5× 673 2.0× 516 2.1× 400 2.0× 273 1.4× 35 1.6k
Claudia Ruiz United States 20 616 1.0× 84 0.3× 126 0.5× 399 2.0× 140 0.7× 36 1.0k
Tony Eight Lin Taiwan 18 644 1.1× 109 0.3× 71 0.3× 175 0.9× 220 1.1× 60 881
Markus Pietsch Germany 20 461 0.8× 145 0.4× 97 0.4× 348 1.7× 68 0.3× 53 982
Letizia Crocetti Italy 19 466 0.8× 119 0.4× 57 0.2× 306 1.5× 114 0.6× 63 866
Xuewei Wu China 15 693 1.2× 127 0.4× 84 0.3× 463 2.3× 212 1.1× 28 1.3k
Narsimha Reddy Penthala United States 21 440 0.7× 155 0.5× 67 0.3× 578 2.8× 99 0.5× 85 1.1k
Lidia Ciccone Italy 18 484 0.8× 103 0.3× 60 0.2× 117 0.6× 160 0.8× 56 808
Lyudmila Tsurkan United States 18 499 0.8× 382 1.2× 241 1.0× 193 0.9× 161 0.8× 21 1.0k

Countries citing papers authored by Xueyang Jiang

Since Specialization
Citations

This map shows the geographic impact of Xueyang Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xueyang Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xueyang Jiang more than expected).

Fields of papers citing papers by Xueyang Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xueyang Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xueyang Jiang. The network helps show where Xueyang Jiang may publish in the future.

Co-authorship network of co-authors of Xueyang Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Xueyang Jiang. A scholar is included among the top collaborators of Xueyang Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xueyang Jiang. Xueyang Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Xueyang, et al.. (2025). Ligustrazine as a multitarget scaffold in drug design and discovery. Bioorganic & Medicinal Chemistry. 121. 118110–118110. 2 indexed citations
2.
Xing, Jing, Cui-Yun Liu, Yaqi Li, et al.. (2025). Dual advantages of SN38 prodrug nanoassemblies overcome defects of irinotecan and SN38: enhanced stability and activatability. Science China Chemistry. 68(11). 5960–5970. 1 indexed citations
3.
Jiang, Xueyang, Xiaoshen Li, Jie Yan, et al.. (2025). Synergistical effect of CoIn alloy and oxygen vacancies over Co-In-Zr ternary catalysts boosting CO2 hydrogenation to methanol. Carbon Capture Science & Technology. 14. 100376–100376.
4.
5.
Li, Xiaoshen, Qingpeng Cheng, Yingtian Zhang, et al.. (2024). Engineering Lattice Dislocations of TiO2 Support of PdZn−ZnO Dual‐Site Catalysts to Boost CO2 Hydrogenation to Methanol. Angewandte Chemie. 137(13).
6.
Sun, Haopeng, et al.. (2024). Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson’s disease. Bioorganic Chemistry. 148. 107488–107488. 2 indexed citations
7.
Li, Jiaming, et al.. (2024). Identification of 3-methyl-1-(3-methylpyridin-2-yl)-1H-pyrazol-5-ol as promising neuroprotective agent. Bioorganic & Medicinal Chemistry Letters. 114. 129983–129983. 1 indexed citations
8.
Liu, Chang, Weiping Lyu, Jian Xu, et al.. (2023). Discovery of thiazole salt AChE inhibitors and development of thiamine disulfide prodrugs targeting the central nervous system. Bioorganic Chemistry. 139. 106702–106702. 6 indexed citations
9.
Wang, Hongwei, et al.. (2023). Design and synthesis of 9-phenanthranilamide derivatives and the study of anti-inflammatory, antioxidant and neuroprotective activities. Bioorganic Chemistry. 141. 106861–106861. 2 indexed citations
10.
Wang, Hongwei, et al.. (2022). Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment. European Journal of Medicinal Chemistry. 241. 114597–114597. 30 indexed citations
11.
12.
Jiang, Xueyang, Junting Zhou, Yang Wang, et al.. (2020). Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease. European Journal of Medicinal Chemistry. 207. 112751–112751. 30 indexed citations
13.
Wang, Yingming, Lingfei Han, Fulei Liu, et al.. (2020). Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. Colloids and Surfaces B Biointerfaces. 188. 110795–110795. 54 indexed citations
14.
Xu, Yunhui, Xueyang Jiang, Jian Xu, et al.. (2020). A previously undescribed phenylethanoid glycoside from Callicarpa kwangtungensis Chun acts as an agonist of the Na/K-ATPase signal transduction pathway. Phytochemistry. 181. 112577–112577. 6 indexed citations
15.
Jiang, Xueyang, Yang Wang, Yingming Wang, et al.. (2020). Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease. Bioorganic & Medicinal Chemistry. 30. 115940–115940. 26 indexed citations
16.
Jiang, Xueyang, Junting Zhou, Yang Wang, et al.. (2020). PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases. European Journal of Medicinal Chemistry. 210. 112949–112949. 48 indexed citations
17.
Wang, Yang, Xueyang Jiang, Feng Feng, Wenyuan Liu, & Haopeng Sun. (2019). Degradation of proteins by PROTACs and other strategies. Acta Pharmaceutica Sinica B. 10(2). 207–238. 233 indexed citations
18.
Jiang, Xueyang, Tingkai Chen, Junting Zhou, et al.. (2018). Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery. ACS Medicinal Chemistry Letters. 9(3). 171–176. 88 indexed citations
19.
20.
Gu, Kai, Qi Li, Hongzhi Lin, et al.. (2017). Gamma secretase inhibitors: a patent review (2013 - 2015). Expert Opinion on Therapeutic Patents. 27(7). 851–866. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jinqiang Hou Breakdown of academic impact, for papers by Carles Galdeano Breakdown of academic impact, for papers by Claudia Ruiz Breakdown of academic impact, for papers by Tony Eight Lin Breakdown of academic impact, for papers by Markus Pietsch Breakdown of academic impact, for papers by Letizia Crocetti Breakdown of academic impact, for papers by Xuewei Wu Breakdown of academic impact, for papers by Narsimha Reddy Penthala Breakdown of academic impact, for papers by Lidia Ciccone Breakdown of academic impact, for papers by Lyudmila Tsurkan
Rankless by CCL
2026